Suppr超能文献

度洛西汀对广泛性焦虑障碍患者疼痛性躯体症状的短期和长期影响:三项临床试验结果

The short- and long-term effect of duloxetine on painful physical symptoms in patients with generalized anxiety disorder: results from three clinical trials.

作者信息

Beesdo Katja, Hartford James, Russell James, Spann Melissa, Ball Susan, Wittchen Hans-Ulrich

机构信息

Technische Universitaet Dresden, Institute of Clinical Psychology and Psychotherapy, Dresden, Germany.

出版信息

J Anxiety Disord. 2009 Dec;23(8):1064-71. doi: 10.1016/j.janxdis.2009.07.008. Epub 2009 Jul 14.

Abstract

Generalized anxiety disorder (GAD) is associated with painful physical symptoms (PPS). These post hoc analyses of previous trial data assessed PPS and their response to duloxetine treatment in GAD patients. Studies 1 and 2 (n=840) were 9- to 10-week efficacy trials; study 3 (n=887) was a relapse prevention trial comprising a 26-week open-label treatment phase and a 26-week double-blind, placebo-controlled treatment continuation phase. Mean baseline visual analog scale scores (VAS, 0-100; n=1727) ranged from 26 to 37 for overall pain, headache, back pain, shoulder pain, interference with daily activities, and time in pain while awake. In studies 1 and 2, improvement on all VAS scores was greater in duloxetine-treated than in placebo-treated patients (p<or=0.01). In study 3, pain symptoms worsened in responders switched to placebo compared with those maintained on duloxetine (p<or=0.02). In conclusion, duloxetine was efficacious in the short- and long-term treatment of PPS, which are common in GAD patients.

摘要

广泛性焦虑障碍(GAD)与疼痛性躯体症状(PPS)相关。这些对既往试验数据的事后分析评估了GAD患者的PPS及其对度洛西汀治疗的反应。研究1和研究2(n = 840)为为期9至10周的疗效试验;研究3(n = 887)是一项预防复发试验,包括一个为期26周的开放标签治疗阶段和一个为期26周的双盲、安慰剂对照治疗延续阶段。总体疼痛、头痛、背痛、肩痛、对日常活动的干扰以及清醒时疼痛时间的平均基线视觉模拟量表评分(VAS,0 - 100;n = 1727)在26至37之间。在研究1和研究2中,度洛西汀治疗组的所有VAS评分改善均大于安慰剂治疗组(p≤0.01)。在研究3中,与继续使用度洛西汀的患者相比,换用安慰剂的缓解者疼痛症状恶化(p≤0.02)。总之,度洛西汀在PPS的短期和长期治疗中均有效,PPS在GAD患者中很常见。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验